| Literature DB >> 32302309 |
Murad Shaqman1, Khadijeh Al-Abedalla2, Julie Wagner3, Helen Swede4, John Cart Gunsolley5, Effie Ioannidou2.
Abstract
OBJECTIVE: Poor reporting in randomized clinical trial (RCT) abstracts reduces quality and misinforms readers. Spin, a biased presentation of findings, could frequently mislead clinicians to accept a clinical intervention despite non-significant primary outcome. Therefore, good reporting practices and absence of spin enhances research quality. We aim to assess the reporting quality and spin in abstracts of RCTs evaluating the effect of periodontal therapy on cardiovascular (CVD) outcomes.Entities:
Year: 2020 PMID: 32302309 PMCID: PMC7164582 DOI: 10.1371/journal.pone.0230843
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Search Strategy with flow chart representing the identification, screening, eligibility and inclusion stages.
Characteristics of included publications and publishing journals.
| RCT | Year | Journal metrics | Article metrics | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journal | 5 years impact | Impact factor without self-citation | Eigenfactor | Influence factor | Abstract Word count | Authors # | Citations | Registration | Geographic location | Funding | ||
| [ | 2017 | JCP | 4.62 | 3.34 | 0.011 | 1.15 | 208 | 5 | 3 | Yes | Netherlands | Yes |
| [ | 2009 | JP | 3.52 | 3.02 | 0.011 | 0.86 | 241 | 17 | 13 | Yes | USA | Yes |
| [ | 2012 | JCP | 4.62 | 3.34 | 0.011 | 1.15 | 193 | 7 | 20 | Yes | Pakistan | Yes |
| [ | 2015 | Medicine | 2.19 | 1.89 | 0.05 | 0.59 | 237 | 11 | 132 | No | Italy | No |
| [ | 2014 | JCP | 4.62 | 3.34 | 0.011 | 1.15 | 174 | 4 | 198 | No | Brazil | Yes |
| [ | 2015 | JP | 3.52 | 3.02 | 0.011 | 0.86 | 266 | 5 | 113 | Yes | Brazil | Yes |
| [ | 2005 | J Dent Res | 5.72 | 5.07 | 0.02 | 1.55 | 160 | 5 | 40 | No | UK | Yes |
| [ | 2006 | Am Heart J | 4.63 | 4.08 | 0.04 | 2.11 | 346 | 6 | 27 | No | UK | Yes |
| [ | 2016 | Clin Oral Invest | 2.55 | 2.23 | 0.011 | 0.68 | 240 | 5 | 682 | No | China | Yes |
| [ | 2007 | S Med J | 0.96 | 0.81 | 0.002 | 0.32 | 145 | 7 | 36 | No | Turkey | No |
| [ | 2011 | JP | 3.52 | 3.02 | 0.011 | 0.86 | 239 | 3 | 12 | No | India | No |
| [ | 2015 | JP | 3.52 | 3.02 | 0.011 | 0.86 | 277 | 4 | 1 | Yes | India | No |
| [ | 2003 | JCP | 4.62 | 3.34 | 0.011 | 1.15 | 174 | 6 | 27 | No | UK | Yes |
| [ | 2016 | Lasers Surg Med | 2.74 | 2.49 | 0.004 | 0.59 | 249 | 8 | 16 | No | Saudi Arabia | Yes |
| [ | 2011 | J Perio Res | 2.71 | 2.70 | 0.004 | 0.63 | 253 | 5 | 1 | No | Jordan | Yes |
| [ | 2014 | Hypertension | 6.74 | 6.16 | 0.04 | 2.19 | 254 | 13 | 40 | Yes | Australia | Yes |
| [ | 2011 | JCP | 4.62 | 3.34 | 0.011 | 1.15 | 192 | 5 | 1 | Yes | China | Yes |
| [ | 2012 | JP | 3.52 | 3.02 | 0.011 | 0.86 | 310 | 6 | 88 | No | Chile | Yes |
| [ | 2010 | Eur J Oral Sci | 1.91 | 1.57 | 0.003 | 0.56 | 177 | 11 | 24 | No | Australia | Yes |
| [ | 2007 | NEJM | 67.51 | 78.54 | 0.70 | 29.45 | 255 | 10 | 8 | No | UK | Yes |
| [ | 2007 | JCP | 4.62 | 3.34 | 0.011 | 1.15 | 201 | 12 | 240 | No | Turkey | Yes |
| [ | 2008 | JCP | 4.62 | 3.34 | 0.011 | 1.15 | 189 | 9 | 16 | No | Japan | Yes |
| [ | 2009 | JP | 3.52 | 3.02 | 0.011 | 0.86 | 228 | 4 | 5 | No | Brazil | Yes |
| [ | 2017 | JP | 3.52 | 3.02 | 0.011 | 0.86 | 252 | 10 | 25 | Yes | China | Yes |
JCP: Journal of Clinical Periodontology, JP: Journal of Periodontology, J Dent Res: Journal of Dental Research, Am Heart J: American Heart Journal, Clin Oral Invest: Clinical Oral Investigations, J Perio Res: Journal of Periodontal Research, Eur J Oral Sci: European Journal Oral Science, S Med J: Southern Medical Journal, Lasers: Surg Med: Lasers in Surgery and Medicine, NEJM: New England Journal of Medicine.
Descriptive data on primary outcome and interventions.
| CHARACTERISTIC | N = 24 | % | |
|---|---|---|---|
| Nature of primary outcome | |||
| True outcome (CV event) | 0 | 0 | |
| Surrogate outcome | 24 | 100 | |
| Primary outcome source | |||
| Explicitly stated in abstracts | 3 | 13% | |
| Explicitly stated in full texts | 3 | 13% | |
| Based on power analysis | 7 | 29% | |
| Implied in objectives | 11 | 33% | |
| Intervention type | |||
| SRP alone | 14 | 58% | |
| SRP + adjunct | 10 | 42% |
* the outcomes of 11 papers were implied by objectives and were more than one primary outcome, they weren’t included in the spin analysis
Fulfillment (%) of CONSORT items stratified by CONSORT sections.
| CONSORT FOR ABSTRACT CHECK LIST | (NUMBER) PERCENTAGE |
|---|---|
| 12 (50%) | |
| 3 (13%) | |
| 0.0% | |
| 13 (54%) | |
| 22 (92%) | |
| 3 (13%) | |
| 0 (0%) | |
| 0 (0%) | |
| 20 (83%) | |
| 4 (17%) | |
| 3 (13%) | |
| 1 (4%) | |
| 3 (13%) | |
| 3 (13%) | |
| 8 (33%) |
Fulfillment (%) of SPIN items in result and conclusion sections.
| Type of spin | (number) Percentage |
|---|---|
| 1) spin in the result | |
| Focus on statistically significant within-group comparison | 3 (21%) |
| Focus on statistically significant secondary outcomes | 9 (64%) |
| Focus on statistically significant subgroup analyses | 2 (14%) |
| Focus on statistically significant modified population of analyses (eg, per-protocol analyses) | 4 (29%) |
| Focus on statistically significant within- and between-group comparisons for secondary outcomes | 9 (64%) |
| 11 (79%) | |
| 2) spin in the conclusions | |
| Focus only on treatment effectiveness: | |
| 1. Claiming equivalence for statistically nonsignificant results | 0 (0%) |
| 2. Claiming efficacy with no consideration of the statistically nonsignificant primary outcome | 9 (64%) |
| 3. Focusing only on statistically significant results | 6 (43%) |
| Acknowledge statistically nonsignificant results for the primary outcome but emphasize the beneficial effect of treatment | 9 (64%) |
| Acknowledge statistically nonsignificant results for the primary outcome but emphasize other statistically significant results | 9 (64%) |
| Other spin in Conclusions section: | |
| 1. Conclusion ruling out an adverse event on statistically nonsignificant results | 0 (0%) |
| 2. Conclusion focusing on within-group assessment (both treatments are effective/treatment administered in both groups is effective (eg, add-on studies) | 2 (14%) |
| 3. Recommendation to use the treatment | 1 (7%) |
| 4. Focus on another objective | 1 (7%) |
| 5. Comparison with placebo group of another trial | 0 (0%) |
| 6. Statistically nonsignificant subgroup results reported as beneficial | 0 (0%) |
| Others: Inadequate extrapolation to larger population, intervention or outcome | 12 (86%) |
| misleading statements designed to exaggerate or falsely claim efficacy | 7 (50%) |
| 3) Spin in both results and conclusions | 12 (86%) |